Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2009

View Archived Issues

Novel MMP-12 inhibitors synthesized at Wyeth for COPD, asthma

Expanding substrate specificity of botulinum neurotoxins may be useful to treat respiratory diseases

Intercytex temporarily suspends trading of shares on AIM

Cardiome Pharma initiates USD 27.5 million tender offer

Nitec reports phase III results from CAPRA-2 study of Lodotra in RA

Ono reports results from first quarter 2009, ending June 30

Gruenenthal discloses voltage-gated potassium channel activators for pain and other conditions

Merck & Co. describes muscarinic M1 allosteric modulators for Alzheimer's disease therapy

Auspex Pharmaceuticals describes deuterated histamine receptor modulators for allergic rhinitis

Novel biomarkers improve diabetes prediction over traditional risk factors

Aspirin does not prevent vascular events in asymptomatic subjects with low ankle brachial index

Allergan discovers novel antiglaucoma agents

Constrictive remodeling seen with rosiglitazone in diabetic CAD patients

Anti-inflammatory CCR2 antagonists with improved pharmacokinetics identified by GlaxoSmithKline

Depressive symptoms correlate with reduced frontal and temporal brain volumes

Tioga and Ono sign license agreement for asimadoline in Japan, South Korea and Taiwan

FDA committee requests additional clinical trial prior to approval of Vion's Onrigin

FDA recommends randomized clinical trial to support label expansion for Genzyme's Clolar in AML

PTC Therapeutics and Roche sign drug discovery collaboration utilizing GEMS technology

Results from NCI study of PharmaGap's GAP-107-B-8 to be reported in September 2009

FDA approves Meda's nasal antihistamine Astepro for seasonal and perennial allergic rhinitis

Dainippon Sumitomo Pharma to acquire Sepracor through cash tender offer

Bayer Schering Pharma and Algeta sign development and commercialization agreement for Alpharadin

FDA grants fast track designation to Knopp Neurosciences for KNS-760704 in ALS

MethylGene initiates phase II MGCD-265 trial in solid tumors and lung cancer

Acrux to submit NDA to FDA for Axiron for testosterone deficiency in men by end of 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...